Table 3.
Studies evaluating initiation, compliance and adherence with long-term endocrine therapy use.
| Study | Participants | Population Description | Parameter | Risk |
|---|---|---|---|---|
| Initiation | ||||
| Lee et al. [60] | 391,594 | National Cancer Database | >12 months | aOR 1.61, 95% CI 1.52–1.70 |
| Fu et al. [59] | 144,103 | National Cancer Database | >150 days | OR 1.66, 95% CI 1.55–1.77 |
| Reeder-Hayes et al. [61] | 2640 | North Carolina Central Cancer Registry | >12 months | aRR 0.83, 95% CI 0.74–0.93 |
| Camacho et al. [63] | 18,054 | SEER-Medicare Database | >12 months | Black 74%, White 77%, p = 0.023 |
| Bowles et al. [64] | 7777 | Kaiser Permanente | >12 months | RR 0.93, 95% CI 0.87–1.00 |
| Farias et al. [62] | 12,198 | SEER-Medicare Database | >12 months | OR 0.25, 95% CI 0.10–0.62 |
| Adherence and compliance | ||||
| Sheppard et al. [65] | 1925 | Health Maintenance Organizations | OR 0.72, 95%CI 0.57–0.90 | |
| Farias et al. [66] | 1240 | Texas Cancer Registry-Medicaid | OR 0.62, 95% CI 0.44–0.87 | |
| Farias et al. [67] | 1497 | Texas Cancer Registry-Medicaid | OR: 0.45, 95% CI 0.28–0.73 | |
| Camacho et al. [63] | 18,054 | SEER-Medicare Database | Black 74%, White 74% | |
| Heiney et al. [68] | 1532 | A Geospatial Investigation of Breast Cancer | MDR Black 0.934 MDR White 0.957 |
|
| Sheppard et al. [69] | 570 | Women’s Hormonal Initiation and Persistence | OR, 0.43, 95% CI 0.27–0.67 | |